Synlogic, Inc.
SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353ā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.13
Price+0.89%
$0.01
1Y
Price
Market Cap
$13.220m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-4.7%
3y CAGR-11.7%
5y CAGREarnings
-$3.227m
+86.2%
1y CAGR+52.9%
3y CAGR+37.4%
5y CAGREPS
-$0.27
+85.9%
1y CAGR+66.4%
3y CAGR+53.3%
5y CAGRBook Value
$10.325m
$16.555m
Assets$6.230m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$4.004m
+87.4%
1y CAGR+45.4%
3y CAGR+31.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company